Shenzhen Weiguang Biological Products Co Ltd (002880) - Total Assets
Based on the latest financial reports, Shenzhen Weiguang Biological Products Co Ltd (002880) holds total assets worth CN¥3.39 Billion CNY (≈ $496.66 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 002880 book value for net asset value and shareholders' equity analysis.
Shenzhen Weiguang Biological Products Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's total assets have evolved over time, based on quarterly financial data.
Shenzhen Weiguang Biological Products Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shenzhen Weiguang Biological Products Co Ltd's total assets of CN¥3.39 Billion consist of 46.3% current assets and 53.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.3% |
| Accounts Receivable | CN¥301.34 Million | 9.1% |
| Inventory | CN¥793.46 Million | 24.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥161.37 Million | 4.9% |
| Goodwill | CN¥19.23 Million | 0.6% |
Asset Composition Trend (2012–2024)
This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shenzhen Weiguang Biological Products Co market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Weiguang Biological Products Co Ltd's current assets represent 46.3% of total assets in 2024, an increase from 45.2% in 2012.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 21.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 11.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 24.1% of total assets.
Shenzhen Weiguang Biological Products Co Ltd Competitors by Total Assets
Key competitors of Shenzhen Weiguang Biological Products Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Shenzhen Weiguang Biological Products Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.92 | 3.89 | 6.08 |
| Quick Ratio | 0.82 | 1.78 | 4.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥884.55 Million | CN¥1.07 Billion | CN¥937.20 Million |
Shenzhen Weiguang Biological Products Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shenzhen Weiguang Biological Products Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.62 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 14.6% |
| Total Assets | CN¥3.30 Billion |
| Market Capitalization | $853.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Weiguang Biological Products Co Ltd's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shenzhen Weiguang Biological Products Co Ltd's assets grew by 14.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shenzhen Weiguang Biological Products Co Ltd (2012–2024)
The table below shows the annual total assets of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.30 Billion ≈ $482.52 Million |
+14.62% |
| 2023-12-31 | CN¥2.88 Billion ≈ $420.96 Million |
+11.69% |
| 2022-12-31 | CN¥2.58 Billion ≈ $376.91 Million |
+28.56% |
| 2021-12-31 | CN¥2.00 Billion ≈ $293.18 Million |
+9.11% |
| 2020-12-31 | CN¥1.84 Billion ≈ $268.69 Million |
+15.82% |
| 2019-12-31 | CN¥1.59 Billion ≈ $231.99 Million |
+8.64% |
| 2018-12-31 | CN¥1.46 Billion ≈ $213.54 Million |
+6.16% |
| 2017-12-31 | CN¥1.37 Billion ≈ $201.16 Million |
+51.08% |
| 2016-12-31 | CN¥909.88 Million ≈ $133.14 Million |
+6.30% |
| 2015-12-31 | CN¥855.97 Million ≈ $125.25 Million |
+11.22% |
| 2014-12-31 | CN¥769.59 Million ≈ $112.62 Million |
+7.97% |
| 2013-12-31 | CN¥712.79 Million ≈ $104.30 Million |
+7.08% |
| 2012-12-31 | CN¥665.63 Million ≈ $97.40 Million |
-- |
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous inj… Read more